Optain
Optain Health is a global medical device and software company specializing in AI-enabled retinal imaging technology for early disease detection. Their flagship product, Eyetelligence Assure, is a software as a medical device (SaMD) that analyzes retinal images to detect eye diseases such as glaucoma, diabetic retinopathy, and age-related macular degeneration, as well as cardiovascular disease risk. The company offers a turnkey solution combining AI software with a portable automatic fundus camera, enabling clinicians to capture and analyze high-quality retinal images quickly and non-invasively. Optain's technology is clinically validated, trained on over 1,000,000 retinal images, and designed to improve diagnostic speed, democratize access to specialized screening, and reduce missed diagnoses. The company is led by experts in ophthalmology AI and has a strong research foundation with peer-reviewed publications. Their business model includes SaaS and device sales, targeting healthcare providers and clinics worldwide, with partnerships including Northwell Health and Aegis Ventures.
Optain
Optain Health is a global medical device and software company specializing in AI-enabled retinal imaging technology for early disease detection. Their flagship product, Eyetelligence Assure, is a software as a medical device (SaMD) that analyzes retinal images to detect eye diseases such as glaucoma, diabetic retinopathy, and age-related macular degeneration, as well as cardiovascular disease risk. The company offers a turnkey solution combining AI software with a portable automatic fundus camera, enabling clinicians to capture and analyze high-quality retinal images quickly and non-invasively. Optain's technology is clinically validated, trained on over 1,000,000 retinal images, and designed to improve diagnostic speed, democratize access to specialized screening, and reduce missed diagnoses. The company is led by experts in ophthalmology AI and has a strong research foundation with peer-reviewed publications. Their business model includes SaaS and device sales, targeting healthcare providers and clinics worldwide, with partnerships including Northwell Health and Aegis Ventures.
TL;DR
What they do: AI-enabled retinal imaging (SaMD) plus portable fundus camera for point-of-care screening
Flagship product: Eyetelligence Assure (AI software) with a turnkey camera solution
Clinical scale: Models trained on over 1,000,000 retinal images
Use cases: Screening for diabetic retinopathy, glaucoma, AMD and cardiovascular risk in primary care and health systems
Reported seed / early institutional investment (US$12M) to support U.S. launch